Search
JinFan Biomedical Technology (Wuhan) Co., Ltd. has recently declared the triumphant conclusion of its A+ round of financing, amassing close to 100 million yuan. This financing endeavor was spearheaded by Wuhan Hi-Tech State-owned Holdings Group, with additional support from Wuhan Huagong Venture Capital. The capital acquired will empower JinFan Medicine to further solidify its position in the gene therapy arena and carve out a new niche in the In vivo CAR-T cell therapy domain. As a pioneering CRO/CDMO enterprise specializing in gene and cell therapy, JinFan Medicine places a premium on technological innovation, boasts all-encompassing service capabilities throughout the entire chain, and has erected distinctive technological barriers in several avant-garde fields.
-
C114 Communication Network -
Communication Home
